Statement of Beneficial Ownership (sc 13d)
November 23 2015 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment No. ________)*
SYNERGY
CHC CORP.
(Name
of Issuer)
COMMON
STOCK
(Title
of Class of Securities)
87165D
109
(CUSIP
Number)
Michel
Loustric
The
Business Center, Upton, St Michael BB11103 Barbados
(246)
266-8631
(Name,
Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
NOVEMBER
12, 2015
(Date
of Event which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect
to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
CUSIP
No. 87165D 109 |
13D |
Page
2 of 5 Pages |
|
|
|
|
|
|
|
|
|
|
|
1. |
|
NAMES
OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Knight Therapeutics (Barbados) Inc. |
|
|
2. |
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) o
(b) o |
|
|
3. |
|
SEC
USE ONLY |
|
|
4. |
|
SOURCE OF FUNDS (see instructions)
OO |
|
|
5. |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) o |
|
|
6. |
|
CITIZENSHIP
OR PLACE OF ORGANIZATION Barbados |
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY
EACH
REPORTING
PERSON
WITH |
|
|
|
7. |
|
SOLE
VOTING POWER 18,277,8141 |
8. |
|
SHARED
VOTING POWER 0 |
9. |
|
SOLE
DISPOSITIVE POWER 18,277,8141 |
10. |
|
SHARED
DISPOSITIVE POWER 0 |
|
|
|
|
|
11. |
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
18,277,8141 |
|
|
12. |
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ¨ |
|
|
13. |
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
21.7%2 |
|
|
14. |
|
TYPE
OF REPORTING PERSON (see instructions) CO |
|
|
|
|
|
|
|
CUSIP No. 87165D
109 |
|
13D |
|
Page
3 of 5 Pages |
|
|
|
|
|
Item
1. Security and Issuer.
(a)
(b)
(c) |
Name
of Issuer:
Synergy
CHC Corp.
Title
of Class of Securities
Common
Stock, par value $0.00001 per share
Address
of Issuer’s Principal Executive Offices
865
Spring Street, Westbrook ME 04092
|
|
|
Item
2. Identity and Background.
(a) |
Name
of Person Filing
Knight Therapeutics (Barbados) Inc.
|
(b) |
Address
of the Principal Office or, if none, residence
The Business Center, Upton, St. Michael Barbados BB11103
|
(c) |
Citizenship
Barbados
|
(d) |
Title
of Class of Securities
Common Stock, par value $0.00001 per share
|
(e) |
CUSIP Number
87165D 109 |
Item
3. Source or Amount of Funds or Other Consideration.
No funds
were used in the acquisition of the securities as they were acquired by the Reporting Person in conjunction with the issuance
of a debenture by the Reporting Person to the Issuer.
Item
4. Purpose of Transaction.
As reported
in Item 3 above, the Reporting Person acquired the securities from the Issuer in conjunction with the issuance of a debenture
by the Reporting Person to the Issuer.
The
Reporting Person expects to evaluate on an ongoing basis the Issuer’s financial condition and prospects and its interest
in, and intentions with respect to, the Issuer and their investment in the securities of the Issuer, which review may be based
on various factors, including whether various strategic transactions have occurred or may occur, the Issuer’s business and
financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in
general and those for the Issuer’s securities in particular, as well as other developments and other investment opportunities.
Accordingly, the Reporting Person reserves the right to change its intentions and develop plans or proposals at any time, as it
deems appropriate.
In particular,
the Reporting Person may at any time and from time to time, (i) in the open market, in privately negotiated transactions or otherwise,
acquire additional securities of the Issuer, including acquisitions from affiliates of the Reporting Person; (ii) dispose of or
transfer all or a portion of the securities of the Issuer that the Reporting Person now owns or may hereafter acquire; or (iii)
enter into derivative transactions with institutional counterparties with respect to the Issuer’s securities. Such suggestions
or positions may include one or more plans or proposals that relate to or would result in any of the actions required to be reported
herein.
|
|
|
|
|
CUSIP No. 87165D
109 |
|
13D |
|
Page
4 of 5 Pages |
|
|
|
|
|
Item
5. Interest in Securities of the Issuer.
(a) |
|
Amount
beneficially owned: 18,277,8141 which represents 21.7%2 of the class |
|
|
|
|
|
|
|
|
(b) |
|
Number
of shares as to which the person has: |
|
|
|
|
|
|
(i) |
Sole
power to vote or to direct the vote: 18,277,8141
|
|
|
(ii) |
Shared
power to vote or to direct the vote: 0
|
|
|
(iii) |
Sole
power to dispose or to direct the disposition of: 18,277,8141
|
|
|
(iv) |
Shared power to
dispose or to direct the disposition of: 0 |
|
|
|
|
(c) |
|
On
November 12, 2015 the Reporting Person acquired beneficial ownership of 10,097,8683 securities of the class in
conjunction with the issuance of a debenture by the Reporting Person to the Issuer. |
|
|
|
Item
6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Not
applicable
Item
7. Material to Be Filed as Exhibits.
|
|
|
|
1 |
|
|
Synergy
CHC Corp. Common Stock Purchase Warrant, dated November 12, 2015 (incorporated by reference to Exhibit 4.4 of the Issuer’s
Current Report on Form 8-K filed with the SEC on November 18, 2015). |
|
|
|
|
2 |
|
|
Synergy
CHC Corp. Common Stock Purchase Warrant (10-Year Warrant), dated November 12, 2015 (incorporated by reference to Exhibit 4.5
of the Issuer’s Current Report on Form 8-K filed with the SEC on November 18, 2015). |
|
|
|
|
3 |
|
|
First Amendment
to Loan Agreement, dated November 12, 2015, between Knight Therapeutics (Barbados) Inc. and Synergy Strips Corp (incorporated
by reference to Exhibit 10.15 of the Issuer’s Current Report on Form 8-K filed with the SEC on November 18, 2015). |
1
Includes 8,132,002 shares that may be acquired upon the exercise of warrants.
2
Based on 84,360,097 shares of common stock issued and outstanding (69,238,044 shares of common stock as reported in the
issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 16, 2015, plus 15,122,053 shares of common stock issued
pursuant to the transactions described on the Form 8-K filed by the issuer with the SEC on November 18, 2015).
3
Includes 5,550,625 shares of common stock acquired upon the exercise of a warrant issued to the Reporting Person on November
12, 2015 for $1.00, and 4,547,243 shares that may be acquired upon the exercise of warrants.
|
|
|
|
|
CUSIP No. 87165D
109 |
|
13D |
|
Page
5 of 5 Pages |
|
|
|
|
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
|
COMPANY NAME |
|
|
|
/s/
Michel Loustric
|
|
Insert
Name |
|
|
|
President
|
|
Insert
Title |
|
|
|
11/23/2015
|
|
Insert
Date |
Synergy CHC (CE) (USOTC:SNYR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Synergy CHC (CE) (USOTC:SNYR)
Historical Stock Chart
From Jul 2023 to Jul 2024